



March 31, 2011

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST)

Subject: REVISED Preliminary Report for Panel Shipment November 8, 2010

Dear Participant:

Attached you will find the REVISED preliminary susceptibility testing results for the cultures of *M. tuberculosis* sent to your laboratory in November 2010. These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the CDC recommends the broth-based methods for routine *M. tuberculosis* drug susceptibility testing, this preliminary report provides the results obtained by using the reference agar proportion method, except in the case of pyrazinamide, where BACTEC MGIT 960 is the reference method. Participants should use the equivalent critical concentrations for testing methods, as defined in CLSI M-24A standards, to determine their results.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. A detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) *M. tuberculosis* complex isolates will be emailed to you before the next scheduled shipment.

For additional information or to comment on this report, you may call Suzette Brown at 1-888-465-6062 or 404 498-2283 or email mtbntmdst@cdc.gov or snp4@cdc.gov. You may also contact Beverly Metchock at 404 639-1285 or email BMetchock@cdc.gov.

We appreciate your continued interest and participation in the CDC Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST).

Sincerely yours,

Suzette Brown, MS

Project Coordinator

NCEZID/DPEI

Centers for Disease Control and Prevention

Ph : 404 498-2283 Fax : 404 498-2215

email : snp4@cdc.gov

**Preliminary Report****Susceptibility Testing Results:
M. tuberculosis Isolates
Panel Shipment November 8, 2010**

Isolate	Susceptibility Testing Results
A	Resistant to Ethambutol (EMB) @ 5µg/ml Resistant to Streptomycin (SM) @ 2µg/ml
B	Resistant to Isoniazid (INH) @ 0.2µg/ml Resistant to Ethionamide (ETH) @ 5µg/ml
C	Resistant to Isoniazid (INH) @ 0.2µg/ml Resistant to Ethambutol (EMB) @ 5µg/ml Resistant to Ethionamide (ETH) @ 5µg/ml
D	Resistant to Isoniazid (INH) @ 0.2µg/ml Resistant to Ethambutol (EMB) @ 5µg/ml Resistant to Ethionamide (ETH) @ 5µg/ml
E	Resistant to Ethambutol (EMB) @ 5µg/ml Resistant to Streptomycin (SM) @ 2µg/ml